Boothbay Fund Management’s Mereo BioPharma MREO Stock Holding History

Boothbay Fund Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-120,584	Closed	-$156K	–	1859
2023 Q3	$156K	Sell	120,584 -61,140	-34%	-$81.1K	﹤0.01%	1482
2023 Q2	$240K	Sell	181,724 -245,679	-57%	-$285K	0.01%	1414
2023 Q1	$302K	Buy	+427,403	New	+$385K	0.01%	1500
2022 Q3	–	Sell	-55,532	Closed	-$62K	–	2469
2022 Q2	$62K	Sell	55,532 -27,051	-33%	-$21K	﹤0.01%	2058
2022 Q1	$92K	Hold	82,583	–	–	﹤0.01%	2114
2021 Q4	$132K	Sell	82,583 -4,837	-6%	-$9.67K	﹤0.01%	1650
2021 Q3	$212K	Sell	87,420 -40,628	-32%	-$108K	0.01%	1542
2021 Q2	$406K	Sell	128,048 -20,000	-14%	-$67.1K	0.01%	1109
2021 Q1	$499K	Buy	148,048 +20,000	+16%	+$70.7K	0.02%	948
2020 Q4	$458K	Sell	128,048 -5,586	-4%	-$14K	0.02%	785
2020 Q3	$350K	Buy	+133,634	New	+$391K	0.02%	768

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Boothbay Fund Management's MREO Position: Q4 2023 in Review

Boothbay Fund Management sold out of Mereo BioPharma (MREO) in Q4 2023, closing a stake of 120,584 shares — an estimated $156K sold.

Boothbay Fund Management first reported a position in MREO in Q3 2020 and held it in 11 quarters. The position peaked at $499K in Q1 2021. 64 funds tracked by Wall St. Rank hold MREO as of Q4 2023.

Boothbay Fund Management reported no remaining Mereo BioPharma position as of Q4 2023 after selling out during the quarter.
Boothbay Fund Management sold 120,584 Mereo BioPharma shares in Q4 2023, an estimated $156K.
Boothbay Fund Management first reported a position in Mereo BioPharma in Q3 2020 and held it in 11 quarters.
Boothbay Fund Management's Mereo BioPharma position peaked at $499K in Q1 2021.
64 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2023.

Based on Boothbay Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.